Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Marker Therapeutics, Inc.MRKR · Entity 7609 | Chief Medical Officer | February 27, 2023 | March 01, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Marker Therapeutics, Inc.
Report date February 27, 2023 · Filed March 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2033-02-27 | Direct | 51,918 |
Reported balance
After 2023-02-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-27 · Grant · Acquired 51,918 · Balance 51,918 F1: This option vests in equal monthly installments over a four year period commencing on March 27, 2023 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in equal monthly installments over a four year period commencing on March 27, 2023 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2023 Filed Mar 1, 2023 21:51 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantEmployee Stock Option (right to buy) · Derivative | 51,918 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-014165 · doc4.xml · derivative · entry 1 Koneru Mythili · CIK 0001776659 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,918 Underlying: Common Stock · 51,918 shares Expires 2033-02-27 F1 · derivative.exercise_date: This option vests in equal monthly installments over a four year period commencing on March 27, 2023 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:07 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantEmployee Stock Option (right to buy) · Derivative | 160,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001209191-22-011779 · doc4.xml · derivative · entry 1 Koneru Mythili · CIK 0001776659 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2032-02-17 F1 · derivative.exercise_date: This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:34 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantEmployee Stock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0001209191-21-010297 · doc4.xml · derivative · entry 1 Koneru Mythili · CIK 0001776659 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2031-02-10 F1 · derivative.exercise_date: This option vests in equal monthly installments over a four year period commencing on March 10, 2021 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:40 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantEmployee Stock Option (Right to Buy) · Derivative | 116,100 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-20-018535 · doc4.xml · derivative · entry 2 Koneru Mythili · CIK 0001776659 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,100 Underlying: Common Stock · 116,100 shares Expires 2030-03-10 F2 · derivative.exercise_date: This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:40 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantEmployee Stock Option (Right to Buy) · Derivative | 23,900 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-20-018535 · doc4.xml · derivative · entry 1 Koneru Mythili · CIK 0001776659 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,900 Underlying: Common Stock · 23,900 shares Expires 2030-03-10 F1 · derivative.exercise_date: Represents a bonus for 2019 performance granted under the Company's 2014 Omnibus Stock Ownership Plan. This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.